48 completed, 16 unknown, 14 recruiting, 10 terminated. 108 Phase 3, 16 Phase 2.
Follow Glioblastoma: new trials by email Literature Review of Glioblastoma trials Research Report on Glioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Contrast-enhanced Magnetic Resonance Imaging, Magnetic Resonance Imaging - Glioblastoma | Phase 3 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 60 | 2026-12-01 | 2026-07-07 |
| Intraoperative Ultrasound for Brain Tumor Surgery Enhanced by AI BrainUS-AI real-time intraoperative ultrasound segmentation system - Brain Tumor Adult | Phase 3 | Not yet recruiting | Hospital del Rio Hortega | 100 | 2026-12-01 | 2026-09-17 |
| Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma Tris-CAR-T cell injection, Ommaya reservoir implantation, Temozolomide (TMZ) - Newly Diagnosed Glioblastoma, IDH-wildtype | Phase 2 / Phase 3 | Not yet recruiting | Beijing Tiantan Hospital | 60 | 2026-10-15 | 2026-10-14 |
| Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma | Phase 3 | Recruiting | NRG Oncology | 398 | 2026-07-16 | 2026-09-10 |
| Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma Dendritic Cell Vaccine, Pembrolizumab, Placebo - Glioblastoma | Phase 3 | Not yet recruiting | University of Sao Paulo General Hospital | 186 | 2026-01-01 | 2025-04-01 |
| Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care GammaTile®, External Beam Radiation Therapy, Temozolomide - Glioblastoma | Phase 3 | Recruiting | GT Medical Technologies, Inc. | 766 | 2025-12-10 | 2026-10-05 |
| Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma TLX-101-Tx + Lomustine, TLX101-Tx - Neoplastic Disease, Glioblastoma | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 50 | 2025-11-02 | 2026-08-11 |
| Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients Biospecimen Collection, Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Diffusion-Relaxation Correlation Spectrum Imaging - Glioblastoma | Phase 3 | Recruiting | Jonsson Comprehensive Cancer Center | 15 | 2025-10-27 | 2026-03-10 |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma Optune® device, Temozolomide, Pembrolizumab - Glioblastoma | Phase 3 | Recruiting | NovoCure GmbH | 741 | 2025-02-03 | 2026-08-19 |
| Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma Temozolomide, Lomustine - Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma | Phase 3 | Recruiting | Vastra Gotaland Region | 200 | 2025-02-01 | 2026-04-13 |
| Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma Hypofractionated radiotherapy, Conventional radiotherapy, Temozolomide - Glioblastoma | Phase 3 | Recruiting | Severance Hospital | 178 | 2025-02-01 | 2025-05-21 |
| Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients Administration of L-TC, Radiotherapy plus Temozolomide - Glioblastoma | Phase 3 | Not yet recruiting | Institut de cancérologie Strasbourg Europe | 554 | 2025-01-01 | 2024-06-27 |
| Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma ICT-107, Placebo - Glioblastoma Multiforme | Phase 3 | Suspended | Precision Life Sciences Group | 234 | 2024-12-01 | 2024-04-03 |
| A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound - Glioblastoma Multiforme, Glioblastoma | Phase 3 | Recruiting | NaviFUS Corporation | 32 | 2024-11-08 | 2026-04-09 |
| A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma Niraparib, Temozolomide - Glioblastoma, GBM | Phase 3 | Active not recruiting | Ivy Brain Tumor Center | 450 | 2024-06-19 | 2026-07-01 |
| Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study Lomustine, Reirradiation - First Progression of Glioblastoma | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 411 | 2024-03-15 | 2026-06-08 |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM SonoCloud-9 (SC9), Carboplatin, Lomustine - Glioblastoma, Recurrent Glioblastoma | Phase 3 | Recruiting | CarThera | 560 | 2024-01-29 | 2026-10-05 |
| Antisecretory Factor Glioblastoma Phase 2 Salovum, Placebo egg yolk powder - Glioblastoma | Phase 2 / Phase 3 | Recruiting | Peter Siesjö | 300 | 2024-01-15 | 2026-01-09 |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) safusidenib, Placebo - Glioma, Astrocytoma, Grade IV | Phase 3 | Recruiting | Nuvation Bio Inc. | 365 | 2023-06-05 | 2026-10-19 |
Showing 20 of 108. Sign in to see all of them.
Brain Neoplasms (32) · Astrocytoma (24) · Glioma (21) · Gliosarcoma (20) · Central Nervous System Neoplasms (13) · Neoplasms (11) · Oligodendroglioma (8) · Recurrence (6) · Choroid Plexus Neoplasms (3) · Ependymoma (3) · Glioma, Subependymal (3) · Medulloblastoma (3) · Meningioma (3) · Neuroectodermal Tumors, Primitive (3)
Neoplasms by Histologic Type (108) · Neoplasms, Germ Cell and Embryonal (108) · Neoplasms, Glandular and Epithelial (108) · Neuroectodermal Tumors (108) · Neoplasms, Nerve Tissue (107) · Neoplasms, Neuroepithelial (106) · Neoplasms (97) · Glioma (87) · Astrocytoma (84) · Neoplasms by Site (39) · Nervous System Diseases (39) · Nervous System Neoplasms (39) · Brain Diseases (33) · Central Nervous System Diseases (33) · Central Nervous System Neoplasms (26)
Temozolomide (49) · Radiotherapy (20) · Lomustine (17) · Bevacizumab (12) · Radiation (9) · Carmustine (8) · Magnetic Resonance Spectroscopy (5) · Procarbazine (4) · Drug Therapy (3) · Surgical Procedures, Operative (3) · ABT-414 (2) · Carboplatin (2) · DNA Methylation (2) · Dianhydrogalactitol (2) · Dihematoporphyrin Ether (2)
European Organisation for Research and Treatment of Cancer - EORTC (5) · NRG Oncology (3) · Radiation Therapy Oncology Group (3) · Sun Yat-sen University (3) · AbbVie (2) · Assistance Publique - Hôpitaux de Paris (2) · INSYS Therapeutics Inc (2) · Jonsson Comprehensive Cancer Center (2) · National Cancer Institute (NCI) (2) · NovoCure Ltd. (2) · Pfizer (2) · Wake Forest University Health Sciences (2) · AHS Cancer Control Alberta (1) · Amsterdam UMC, location VUmc (1) · Ascletis Pharmaceuticals Co., Ltd. (1)
United States (53) · Canada (30) · Germany (27) · France (26) · Netherlands (17) · United Kingdom (17) · Spain (16) · Australia (14) · Austria (14) · Switzerland (14) · China (13) · Italy (12) · Israel (11) · Belgium (10) · South Korea (9)
Roger Stupp, MD (4) · Alba A. Brandes, MD (1) · Alexander M. Spence, MD (1) · Alison L. Hannah, MBBS (1) · Andrey S. Bryukhovetskiy, MD (1) · Andriy Markivskyy, MD (1) · Asgeir S Jakola, MD, PhD (1) · Brigitta Baumert, MD, PhD (1)
PMID 32691060, PMID 36346112, PMID 10549493, PMID 15251162, PMID 15465203, PMID 15727424, PMID 15758009, PMID 15758010, PMID 15890570, PMID 16033132, PMID 16203762, PMID 16321761, PMID 16520474, PMID 16735709, PMID 17429084, PMID 17609661, PMID 18082451, PMID 18455252, PMID 19269895, PMID 20124186, PMID 20383558, PMID 20855843, PMID 21715171, PMID 21880994, PMID 22480131, PMID 22578793, PMID 22608262, PMID 22847020, PMID 23529375, PMID 23545055, PMID 23817721, PMID 23940216, PMID 24101040, PMID 24117272, PMID 24552317, PMID 24552318, PMID 24563781, PMID 25163906, PMID 25303679, PMID 25407559, PMID 25688120, PMID 25789053, PMID 26014298, PMID 26189058, PMID 26392096, PMID 26615020, PMID 26670971, PMID 26809751, PMID 27006178, PMID 27020837
U10CA180868 (3), 2023 (2), 2008 (1), 2009 (1), 2015 (1), 2017 (1), 2018 (1), 2025 (1), KL2TR001882 (1), P30CA016672 (1), P30CA043703 (1), P50CA108961 (1), U10CA021661 (1), U10CA031946 (1), U10CA032102 (1)